Show simple item record

dc.contributor.advisorDouglas Lauffenburger and Roy Welsch.en_US
dc.contributor.authorCárcamo Behrens, Martín.en_US
dc.contributor.otherSloan School of Management.en_US
dc.contributor.otherMassachusetts Institute of Technology. Department of Biological Engineering.en_US
dc.contributor.otherLeaders for Global Operations Program.en_US
dc.date.accessioned2019-11-22T00:08:41Z
dc.date.available2019-11-22T00:08:41Z
dc.date.copyright2019en_US
dc.date.issued2019en_US
dc.identifier.urihttps://hdl.handle.net/1721.1/123055
dc.descriptionThesis: M.B.A., Massachusetts Institute of Technology, Sloan School of Management, in conjunction with the Leaders for Global Operations Program at MIT, 2019en_US
dc.descriptionThesis: S.M., Massachusetts Institute of Technology, Department of Biological Engineering, in conjunction with the Leaders for Global Operations Program at MIT, 2019en_US
dc.descriptionCataloged from PDF version of thesis.en_US
dc.descriptionIncludes bibliographical references (pages 86-99).en_US
dc.description.abstractBreaking the trade-off between speed and productivity is a key milestone across industries. In particular, in the biopharmaceutical industry this trade-off is exacerbated by a highly regulated environment, which hinders continuous improvement and fixes future manufacturing costs. Given the complexity of living organisms and the improvement in quality of life offered by the product - which demand agile development - the industry has traditionally taken phenomenological approaches to process development, generally sacrificing costs. Nonetheless, technological developments and lower entry barriers make the biopharmaceutical industry far more competitive than in its origins, demanding efficient and reliable processes. Developing efficient manufacturing processes for new products while being agile to market is a key differentiating capability of Amgen's process development organization.en_US
dc.description.abstractIn collaboration with the process development team at Amgen, a computational framework for in-silico upstream bioprocess development has been developed, allowing for faster, more robust, and more optimal process development. Specifically, a mechanistic model of a bioreactor has been designed, implemented, and applied to an Amgen product. The project was divided into three major components: The first was a survey of internal Amgen capabilities and the state of the art in external industrial and academic models to identify the algorithms and design the signal flow required to support the range of expected process engineering applications. The second consisted of implementing a modular, extensible software platform with the architecture and interfaces dictated by the first component. The third part consisted of applying the software to an actual product development problem capturing the primary process variables.en_US
dc.description.abstractA constraint-based model of a metabolic network consisting of 35 reactions of the main carbon-nitrogen metabolism relevant in energy and redox balance was adapted from literature (Nolan & Lee, 2011). The metabolic network was coupled with glucose, glutamine and asparagine kinetics with temperature, dissolved oxygen, pH and osmolarity dependence. Stress induced by temperature shifts was modeled as a first-order step response coupled to a non-growth associated ATP of maintenance. The cellular model was coupled with a well-mixed bioreactor model consisting of mass balance equations. We solved the model using dynamic Flux Balance Analysis (dFBA). We first calibrated the model with experimental process characterization data for a product in development. We used a Non-dominated Sorted Genetic Algorithm (NSGA-II) to solve the calibration problem, minimizing the error in metabolite concentrations to yield estimates of 13 strain-specific parameters.en_US
dc.description.abstractWe then assessed the calibrated model's predictions of biomass growth and metabolite concentrations against a second experiment run with different process settings. Finally, I developed a graphical user interface for subject-matter-experts to simulate experiments and test hypotheses using the model. We applied the tool to three process-relevant case studies, and analyzed the in-silico results. The calibrated model can predict biomass and titer from process settings, potentially reducing experimental time from 20 days to 30 seconds, in addition to reducing the experimental cost.en_US
dc.description.statementofresponsibilityby Martín Cárcamo Behrens.en_US
dc.format.extent99 pagesen_US
dc.language.isoengen_US
dc.publisherMassachusetts Institute of Technologyen_US
dc.rightsMIT theses may be protected by copyright. Please reuse MIT thesis content according to the MIT Libraries Permissions Policy, which is available through the URL provided.en_US
dc.rights.urihttp://dspace.mit.edu/handle/1721.1/7582en_US
dc.subjectSloan School of Management.en_US
dc.subjectBiological Engineering.en_US
dc.subjectLeaders for Global Operations Program.en_US
dc.titleA computational framework for predicting CHO cell culture performance in bioreactorsen_US
dc.title.alternativeComputational framework for predicting Chinese hamster ovary cell culture performance in bioreactorsen_US
dc.typeThesisen_US
dc.description.degreeM.B.A.en_US
dc.description.degreeS.M.en_US
dc.contributor.departmentSloan School of Managementen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineeringen_US
dc.contributor.departmentLeaders for Global Operations Programen_US
dc.identifier.oclc1127288835en_US
dc.description.collectionM.B.A. Massachusetts Institute of Technology, Sloan School of Managementen_US
dc.description.collectionS.M. Massachusetts Institute of Technology, Department of Biological Engineeringen_US
dspace.imported2019-11-22T00:08:40Zen_US
mit.thesis.degreeMasteren_US
mit.thesis.departmentSloanen_US
mit.thesis.departmentBioEngen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record